Evidence map›Paper›PMID 37085291›Full record

ArticleCanadian journal of surgery. Journal canadien de chirurgie

Total neoadjuvant therapy for rectal cancer: a guide for surgeons.

Garrett G R J Johnson, Jason Park, Ramzi M Helewa, Benjamin A Goldenberg, Maged Nashed, Eric Hyun

2 registry-linked trialsOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of surgery. Journal canadien de chirurgie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07314528. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07314528 phase2not yet recruiting

A Phase II Multi-institutional Randomized Trial Evaluating the Impact of GLP-1 Receptor Agonists in Combination With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Ran2026Enrolled42Registered outcomes23Posted comparisons0ConditionsGLP-1, Locally Advanced Rectal Cancer (LARC), Obesity &Amp; Overweight, Rectal Cancer PatientsArmsGLP-1 receptor agonist, Total neoadjuvant therapy (TNT)
PMID 33567185PMID 35565381PMID 36294412PMID 40437949PMID 40285503PMID 40140925PMID 39093546PMID 38967919PMID 38893212PMID 38888262PMID 32923389other papers from this trial
Open the trial in the graph
NCT06589388 recruitingnot on this map

ctDNA Monitoring to Predict the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

TypeobservationalSponsorGene SolutionsRan2024 to 2027Enrolled100ConditionsRectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Total neoadjuvant therapy for locally advanced rectal cancer.The Cochrane database of systematic reviews · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Garrett G R J JohnsonFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed).
Jason ParkFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed).
Ramzi M HelewaFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed).
Benjamin A GoldenbergFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed).
Maged NashedFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed).
Eric HyunFrom the Department of Surgery, Section of General Surgery, University of Manitoba, Winnipeg, Man. (Johnson, Helewa, Hyun); the Clinician Investigator Program, University of Manitoba, Winnipeg Man. (Johnson); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Park); the Section of Medical Oncology and Haematology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man. (Goldenberg); the Radiation Oncology, CancerCare Manitoba, Winnipeg, Man. (Nashed) ehyun@sbgh.mb.ca.
CancerCare Manitoba · CAUniversity of Manitoba · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The modern management of rectal cancers continues to evolve. With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal cancer treatment and is considered a standard option in selected patients. Total neoadjuvant therapy promises enhanced systemic disease control, better treatment adherence and less time with an ostomy. However, TNT as currently described encompasses a number of different potential treatment options that differ significantly in terms of their radiation dosage, chemotherapy regimen and order of treatments administered. Being familiar with TNT regimens will be important for rectal cancer surgeons to appropriately advocate for their patients and optimize their outcomes. This article serves as a primer for the general surgeon and offers a pragmatic overview of the indications, realistic expected benefits and potential downsides of each TNT regimen.

Indexed as

Neoadjuvant TherapyRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyHumansNeoplasm StagingRectum

Identifiers

PMID37085291
PMCPMC10125160
OpenAlexW4366742756

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.